ARTD10 Substrate Identification on Protein Microarrays: Regulation of GSK3β by Mono-ADP-ribosylation
Overview
Cell Biology
Authors
Affiliations
Background: Although ADP-ribosylation has been described five decades ago, only recently a distinction has been made between eukaryotic intracellular poly- and mono-ADP-ribosylating enzymes. Poly-ADP-ribosylation by ARTD1 (formerly PARP1) is best known for its role in DNA damage repair. Other polymer forming enzymes are ARTD2 (formerly PARP2), ARTD3 (formerly PARP3) and ARTD5/6 (formerly Tankyrase 1/2), the latter being involved in Wnt signaling and regulation of 3BP2. Thus several different functions of poly-ADP-ribosylation have been well described whereas intracellular mono-ADP-ribosylation is currently largely undefined. It is for example not known which proteins function as substrate for the different mono-ARTDs. This is partially due to lack of suitable reagents to study mono-ADP-ribosylation, which limits the current understanding of this post-translational modification.
Results: We have optimized a novel screening method employing protein microarrays, ProtoArrays®, applied here for the identification of substrates of ARTD10 (formerly PARP10) and ARTD8 (formerly PARP14). The results of this substrate screen were validated using in vitro ADP-ribosylation assays with recombinant proteins. Further analysis of the novel ARTD10 substrate GSK3β revealed mono-ADP-ribosylation as a regulatory mechanism of kinase activity by non-competitive inhibition in vitro. Additionally, manipulation of the ARTD10 levels in cells accordingly influenced GSK3β activity. Together these data provide the first evidence for a role of endogenous mono-ADP-ribosylation in intracellular signaling.
Conclusions: Our findings indicate that substrates of ADP-ribosyltransferases can be identified using protein microarrays. The discovered substrates of ARTD10 and ARTD8 provide the first sets of proteins that are modified by mono-ADP-ribosyltransferases in vitro. By studying one of the ARTD10 substrates more closely, the kinase GSK3β, we identified mono-ADP-ribosylation as a negative regulator of kinase activity.
Zhang X, Yang C, Zhang C, Wu J, Zhang X, Gao J Nat Commun. 2025; 16(1):2174.
PMID: 40038284 PMC: 11880380. DOI: 10.1038/s41467-025-57445-x.
Chan E, Ablooglu A, Ghosh C, Desai A, Schaible N, Chen X Arterioscler Thromb Vasc Biol. 2024; 44(12):2628-2646.
PMID: 39479769 PMC: 11602389. DOI: 10.1161/ATVBAHA.124.321522.
ADP-ribose hydrolases: biological functions and potential therapeutic targets.
Wang J, Wang Z, Zong W Expert Rev Mol Med. 2024; 26:e21.
PMID: 39375922 PMC: 11488344. DOI: 10.1017/erm.2024.17.
Pathological and physiological roles of ADP-ribosylation: established functions and new insights.
Feijs-Zaja K, Ikenga N, Zaja R Biol Chem. 2024; .
PMID: 39066732 DOI: 10.1515/hsz-2024-0057.
HTRF-based assay for detection of mono-ADP-ribosyl hydrolyzing macrodomains and inhibitor screening.
Ildefeld N, Steinhilber D, Proschak E, Heering J iScience. 2024; 27(7):110333.
PMID: 39055912 PMC: 11269945. DOI: 10.1016/j.isci.2024.110333.